Document:

EX-10.7

 Certain identified information has been excluded from this exhibit because it is both
not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Exhibit 10.7 
 AMENDMENT
#1 to the 
 AMENDED AND RESTATED 

COLLABORATION AND LICENSE AGREEMENT 

THIS AMENDMENT #1 (“Amendment”), effective January 21, 2016 (“Amendment Effective Date”), is by and between Pioneer Hi-Bred International, Inc., with headquarters at 7100 NW 62nd Avenue, PO Box 1014, Johnston, Iowa 50131-1014, USA (“Pioneer”), and Caribou Biosciences, Inc., located at 2929 7th St., Suite 120,
‘Berkeley, California 94710 (“Caribou Bio”) (Caribou Bio and Pioneer, each individually a “Party”, and together the “Parties”). 

WHEREAS, the Parties have signed an Amended and Restated Collaboration and License Agreement, which as of July 13, 2015, [***]
“Agreement” refers to the Amended and Restated Collaboration and License Agreement; and 
 WHEREAS, the Parties desire to amend
the Agreement to clarify certain provisions and provide updates to certain Appendices of the Agreement; 
 NOW, THEREFORE, in consideration
of the mutual agreements contained in this Amendment, and for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 

 

	 	1.	 All capitalized terms not defined in this Amendment shall have the meanings set forth in the Agreement.

  

	 	[***]	 

  

	 	3.	 In Section 6.2(a)(iv) of the Agreement, the phrase “DuPont Pioneer Bio Background IP” is deleted
and replaced with “DuPont Pioneer Background IP” as of the Effective Date. 

  

	 	4.	 Section 6.6(a) is deleted in its entirety and replaced with the following Section 6.6(a) as of the
Effective Date: 

  

	 	6.6	 [***] 

  

	 	5.	 Appendix E of the Agreement is hereby amended to append the following: 

 

							
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]

  

	 	6.	 Appendix D-1 (Updated Caribou Bio Background IP as of the Amendment
Effective Date) and Appendix E-1 (Updated DuPont Pioneer Background IP as of the Amendment Effective Date) attached hereto arc appended to the Agreement. 

 

	 	7.	 Appendix H sets forth the Program IP (as defined in Section 1.43(c)) of the Agreement as of the Amendment
Effective Date, 

  

	 	8.	 All other terms of the Agreement remain in full force and effect. 

 

	 	9.	 This Amendment may be executed in any number of counterparts, including facsimile or scanned PDF documents.
Each such counterpart, facsimile or scanned PDF document shall be deemed an original instrument, and all of which, together, shall constitute one and the same executed Agreement. 

[Signature Page Follows] 

 IN WITNESS WHEREOF. the Parties have caused this Amendment #1 to the Amended and Restated
Collaboration and License Agreement to be executed by their respective authorized representatives. 
  

									
	Pioneer Hi-Bred International, Inc.	  		  	Caribou Biosciences, Inc.
					
	By:	 	 /s/ Paul E. Schickler
	  		  	By:	 	 /s/ Rachel E. Haurwitz

	Name:	 	Paul E. Schickler	  		  	Name:	 	Rachel E. Haurwitz
	Title:	 	President	  		  	Title:	 	President and CEO
					
	Date:	 	January 22, 2016	  		  	Date:	 	January 21, 2016

 Appendix E-1 

DuPont Pioneer Background IP 

as of the Amendment Effective Date 

[***] 

 APPENDIX H 

PROGRAM IP 
 As of the
Amendment Effective Date 
 [***]EX-10.8

 Certain identified information has been excluded from this exhibit because it is both
not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Exhibit 10.8 
 AMENDMENT
#2 to the AMENDED AND RESTATED 
 COLLABORATION AND LICENSE AGREEMENT 

This Amendment #2 to the Amended and Restated Collaboration and License Agreement (“Amendment”), effective July 18, 2016 (the
“Amendment #2 Effective Date”), is by and between Pioneer Hi-Bred International, Inc., with headquarters at 7100 NW 62nd Avenue, PO Box 1014,
Johnston, Iowa 50131-1014, USA (“Pioneer”), and Caribou Biosciences, Inc., located at 2929 7th St., Suite 105, Berkeley, California 94710 (“Caribou Bio”) (Caribou Bio and
Pioneer, each individually a “Party”, and together the “Parties”). 
 WHEREAS, the Parties have signed an Amended and
Restated Collaboration and License Agreement dated July 13, 2015 (which as of July 13, 2015, [***] as amended by Amendment #1 to the Amended and Restated Collaboration and License Agreement, dated January 21, 2016. As used in this
Amendment, “Agreement” refers to the Amended and Restated Collaboration and License Agreement, as amended; and 
 WHEREAS, the
Parties desire to further amend the Agreement to clarify certain effects of termination of the Agreement; 
 NOW, THEREFORE, in
consideration of the mutual agreements contained in this Amendment, and for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 

 

	1.	 All capitalized terms not defined in this Amendment shall have the meanings set forth in the Agreement.

  

	2.	 Section 9.3 of the Agreement is hereby amended to include the following Subsection 9.3(c) as of the
Amendment #2 Effective Date: 

  

	“c.	 [***] 

  

	3.	 Section 12.3 of the Agreement is hereby replaced in its entirety with the following: “Assigns and
Successors. 

 [***] 
  

	4.	 All other terms of the Agreement remain in full force and effect. 

 

	5.	 This Amendment may be executed in any number of counterparts, including facsimile or scanned PDF documents.
Each such counterpart, facsimile or scanned PDF document shall be deemed and original instrument, and all of which, together, shall constitute one and the same executed Agreement. 

IN WITNESS WHEREOF, the Parties have caused this Amendment #2 to the Amended and Restated Collaboration and License Agreement to be executed
by their respective authorized representatives. 
  

									
	Pioneer Hi-Bred International, Inc.	 		 	Caribou Biosciences, Inc.
					
	By:	 	 /s/ Mathias L. Müller
	 		 	By:	  	 /s/ Rachel E. Haurwitz

	Name: Mathias L. Müller	 		 	Name: Rachel E. Haurwitz
	Title: Director, Business Development	 		 	Title: President and CEO
			
	Date: July 25, 2016	 		 	Date: July 27, 2016EX-10.9

 Certain identified information has been excluded from this exhibit because it is both
not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Exhibit 10.9 
 AMENDMENT
#3 to the 
 AMENDED AND RESTATED 

COLLABORATION AND LICENSE AGREEMENT 

This Amendment #3 to the Amended and Restated Collaboration and License Agreement (“Amendment”), effective March 13, 2017 (the
“Amendment #3 Effective Date”), is by and between Pioneer Hi-Bred International, Inc., with headquarters at 7100 NW 62nd Avenue, PO Box 1014, Johnston, Iowa 50131-1014, USA (“Pioneer”), and
Caribou Biosciences, Inc., located at 2929 7th St., Suite 105, Berkeley, California 94710 (“Caribou Bio”) (Caribou Bio and Pioneer, each individually a “Party”, and together the “Parties”). 

WHEREAS, the Parties have signed an Amended and Restated Collaboration and License Agreement dated July 13, 2015 (which as of
July 13, 2015, [***] as amended by Amendment #1 to the Amended and Restated Collaboration and License Agreement, dated January 21, 2016 (“Amendment #1), and Amendment #2 to the Amended and Restated Collaboration and License Agreement,
dated July 18, 2016. As used in this Amendment, “Agreement” refers to the Amended and Restated Collaboration and License Agreement, as amended; and 

WHEREAS, the Parties desire to further amend the Agreement to provide an update to an Appendix of the Agreement; 

NOW, THEREFORE, in consideration of the mutual agreements contained in this Amendment, and for good and valuable consideration, the
sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 
  

	1.	 All capitalized terms not defined in this Amendment shall have the meanings set forth in the Agreement.

  

	2.	 Page 6 of Amendment #1 is hereby deleted in its entirety and replaced with the attached schedule setting forth
the patent family owned by The Regents of the University of California/University of Vienna/Emmanuelle Charpentier entitled “Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription.” 

  

	3.	 All other terms of the Agreement remain in full force and effect. 

 

	4.	 This Amendment may be executed in any number of counterparts, including facsimile or scanned PDF documents.
Each such counterpart, facsimile or scanned PDF document shall be deemed an original instrument, and all of which, together, shall constitute one and the same executed Agreement. 

  
 Page 1 of 2 

 IN WITNESS WHEREOF, the Parties have caused this Amendment #3 to the Amended and Restated
Collaboration and License Agreement to be executed by their respective authorized representatives. 
  

									
	Pioneer Hi-Bred International, Inc.	  		  	Caribou Biosciences, Inc.
					
	By:	  	 /s/ Mathias L. Müller
	  		  	By:	  	 /s/ Rachel E. Haurwitz

	Name: Mathias L. Müller	  		  	Name: Rachel E. Haurwitz
	Title: Director, Business Development	  		  	Title: President and CEO
			
	Date: May 5, 2017	  		  	Date: May 9, 2017

  
 Page 2 of 2EX-10.10

 Certain identified information has been excluded from this exhibit because it is both
not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Exhibit 10.10 
 AMENDMENT
#4 to the 
 AMENDED AND RESTATED 

COLLABORATION AND LICENSE AGREEMENT 

This Amendment #4 to the Amended and Restated Collaboration and License Agreement (“Amendment”), effective June 26, 2017 (the
“Amendment #4 Effective Date”), is by and between Pioneer Hi-Bred International, Inc., with headquarters at 7100 NW 62nd Avenue, PO Box 1014, Johnston, Iowa 50131-1014, USA (“Pioneer”), and
Caribou Biosciences, Inc., located at 2929 7th St., Suite 105, Berkeley, California 94710 (’Caribou Bio”) (Caribou Bio and Pioneer, each individually a “Party”, and together the ‘‘Parties”). 

WHEREAS, the Parties have signed an Amended and Restated Collaboration and License Agreement dated July 13, 2015 (which, as of
July 13, 2015, [***] as amended by Amendment# I to the Amended and Restated Collaboration and License Agreement, dated January 21, 2016; Amendment #2 to the Amended and Restated Collaboration and License Agreement, dated July 18,
2016; and Amendment #3 to the Amended and Restated Collaboration and License Agreement, dated March 13, 2017 (collectively, the ‘‘Agreement”); mid 

WHEREAS, the Parties desire to further amend the Agreement to clarify certain aspects of sublicensing by the Parties in the Agreement; 

NOW, THEREFORE, in consideration of the mutual agreements contained in this Amendment, and for good and valuable consideration, the
sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 
  

	1.	 All capitalized terms not defined in this Amendment shall have the meanings set forth in the Agreement.

  

	2.	 Sections 6.3(a)(iv) is hereby amended to introduce the following phrase at the beginning of
Section 6.3(a)(iv): 

 [***] 
  

	3.	 Section 6.3(a) is hereby amended to include the following Subsection 6.3(a)(v): 

[***] 
  

	4.	 Sections 6.3(b)(v) is hereby amended to introduce the following phrase at the beginning of
Section 6.3(b)(v): 

 [***] 
  

	5.	 Section 6.3(b) is hereby amended to include the following Subsection 6.3(b)(vi): 

[***] 
  

	6.	 All other terms of the Agreement remain in full force and effect. 

 

	7.	 This Amendment may be executed in any number of counterparts, including facsimile or scanned PDF documents.
Each such counterpart, facsimile or scanned PDF document shall be deemed an original instrument, and all of which, together, shall constitute one and the same executed Agreement. 

[Signature Page Follows} 

 IN WITNESS WHEREOF, the Parties have caused this Amendment #4 to the Amended and Restated
Collaboration and License Agreement to be executed by their respective authorized representatives. 
  

									
	Pioneer Hi-Bred International, Inc.	  		  	Caribou Biosciences, Inc.
					
	By:	  	 /s/ Mathias L. Müller
	  		  	By:	  	 /s/ Rachel E. Haurwitz

	Name: Mathias L. Müller	  		  	Name: Rachel E. Haurwitz
	Title: Director, Business Development	  		  	Title: President and CEO
			
	Date: June 26, 2017	  		  	Date: June 26, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]